Table 1 Demographic data and clinical characteristics of enrolled patients
Characteristic | Biomarker cohort (n = 50), No (%) | TP53 MUT (n = 16), No (%) | TP53 WT (n = 34), No (%) | p value |
|---|---|---|---|---|
Median age, years (range) | 57 (40–72) | 53 (41–72) | 61 (40–69) | 0.020 |
Sex | ||||
Male | 21 (42.0) | 6 (37.5) | 15 (44.1) | 0.658 |
Female | 29 (58.0) | 10 (62.5) | 19 (55.9) | |
Smoking histology | ||||
Never | 35 (70.0) | 12 (75.0) | 23 (67.6) | 1.000 |
Former | 14 (28.0) | 4 (25.0) | 10 (29.4) | |
Current | 1 (2.0) | 0 (0.0) | 1 (2.9) | |
ECOG performance status | ||||
0 | 7 (14.0) | 1 (6.3) | 6 (17.6) | 0.406 |
1 | 43 (86.0) | 15 (93.8) | 28 (82.4) | |
Clinical stage | ||||
IIIB | 2 (4.0) | 0 (0.0) | 2 (5.9) | 1.000 |
IV | 48 (96.0) | 16 (100.0) | 32 (94.1) | |
No. of metastatic organs | ||||
≤ 2 | 25 (50.0) | 7 (43.8) | 18 (52.9) | 0.544 |
> 2 | 25 (50.0) | 9 (56.3) | 16 (47.1) | |
Prior chemotherapy | ||||
< 2 Lines | 28 (56.0) | 12 (75.0) | 16 (47.1) | 0.063 |
≥ 2 Lines | 22 (44.0) | 4 (25.0) | 18 (52.9) | |
Previous targeted therapy | ||||
No | 38 (76.0) | 13 (81.3) | 25 (73.5) | 0.728 |
Yes | 12 (24.0) | 3 (18.8) | 9 (26.5) | |
Previous radiotherapy | ||||
No | 35 (70.0) | 12 (75.0) | 23 (67.6) | 0.746 |
Yes | 15 (30.0) | 4 (25.0) | 11 (32.4) | |